November 18, 2019
Potential of PK/PD modelling and simulation in drug development through concrete examples
- Monnet et al. Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. 2017, Clin. Pharm. Ther. 101:200-208.
- Melhem et al. Pharmacokinetic-pharmacodynamic modelling of neutrophil Response to G-CSF in healthy subjects and patients with chemotherapy induced neutropenia. Br J Clin Pharmacol. 2018, 84(5):911-925.
- Van Schaick et al. A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling. J Pharmacokinet Pharmacodyn, 2015 42(4):315-32.
Info : Françoise Van Bambeke